All In Biotech

Drug Trial Radar · NCT05659576

Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

142

Actual

Start

Dec 13, 2022

Primary completion

Aug 26, 2026

Study completion Aug 26, 2026

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.

Conditions

  • Radiation Esophagitis

Interventions

  • SucralfateDrug

    1. Sucralfate, 1 gram/10 mL oral suspension "By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime".May increase frequency up to 4 times per day, per physician discretion". Or 2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime". The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion".

  • Usual CareOther

    Standard supportive care by using opioids.

  • One consentOther

    Patient will sign one consent form.

  • Two consentOther

    Patient will sign two consent forms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accrual rate (Two-stage consent part)Time frame: 1 year
  2. Reduce opioid useTime frame: 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jersey

  • Memorial Sloan Kettering Bergen (All Protocol Activities)

    Montvale, New Jersey

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )

    Commack, New York

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York

  • Memorial Sloan Kettering Nassau (All Protocol Activities)

    Uniondale, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.